Breast Conservation Surgery vs Mastectomy: How the Decision Is Made

Prognosis is improving steadily. Five-year survival is around 97-98% for stage one, 90-95% for stage two, 80-85% for stage three, and even stage four disease has a 25-30% five-year survival rate. Triple-negative and locally advanced cases carry a higher recurrence risk specifically, so they need especially stringent follow-up to catch any recurrence early enough to treat.

Surgery alone, all-inclusive, costs roughly $5,000. Chemotherapy adds around $10,000, and radiation is roughly $3,500 to $4,000. Extended targeted therapy such as trastuzumab can add another $10,000, though that portion can often be continued at the patient's home location. As a rough guide, surgery plus basic chemotherapy runs around $15,000 for most patients, and cases involving genuine financial hardship can always be discussed.

A whole-abdomen ultrasound, not just the upper abdomen, checks for liver metastasis and also covers the ovaries and uterus. A chest X-ray checks for lung metastasis. For bone, a skeletal survey, plain X-rays covering the spine, skull and limbs, substitutes for a bone scan where nuclear medicine isn't available. This combination is less accurate than PET CT but is a reasonable, optimal fallback when resources are limited.

For a young patient with early, well-localised disease, breast conservation surgery is advisable over mastectomy: a wide excision with lymph node dissection or sentinel biopsy, followed by pathology review. If the oestrogen receptor is positive on the final specimen, tamoxifen is started after surgery, and chemotherapy is added if indicated by the pathology. Starting tamoxifen before surgery is not advisable.

Neoadjuvant chemotherapy should be started before referral in two situations: triple-negative breast cancer, and locally advanced disease, meaning a tumour over 5 cm, ulceration, peau d'orange skin change, satellite nodules, or bulky or supraclavicular nodes. In locally advanced disease, surgery follows after around four to four and a half months of chemotherapy. In genuinely advanced or metastatic disease, treatment is systemic only, chemotherapy or hormone therapy, with no surgery. For anything in between, it is always better to discuss the specific case jointly before deciding independently whether and when to start treatment.

When there is multicentric disease across more than one quadrant, when the breast is too small for a meaningful cosmetic result after wide excision, or when radiation cannot be given, for example in first-trimester pregnancy, severe SLE, or where radiotherapy is unavailable.

A full 1 cm margin in all directions, superior, inferior, medial, lateral, deep and skin, even though some surgeons consider 5 mm sufficient.